Liam S. Sharninghausen
Liam S. Sharninghausen has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Robert H. Crabtree
Department of Chemistry, Yale University, New Haven, USA
17 shared publications Brandon Q. Mercado
Department of Chemistry, Yale University, 225 Prospect Street, New Haven, Connecticut 06520, United States
12 shared publications- Gary W. Brudvig
Department of Chemistry Yale University New Haven Connecticut USA
10 shared publications - David Balcells
Hylleraas Centre for Quantum Molecular Sciences, Department of Chemistry, University of Oslo, 0315 Oslo, Norway
9 shared publications Dimitar Y. Shopov
Department of Chemistry, Yale University, 225 Prospect Street, New Haven, Connecticut 06520, United States
8 shared publications- Shashi Bhushan Sinha
Department of Chemistry, Yale University , 225 Prospect Street, New Haven, Connecticut 06520, United States
8 shared publications
Latest Publications
- 13 October 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (11) , 2636-2648
A Second-Generation Route to the Cereblon Fragment of ARV-471, Vepdegestrant
- 13 October 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (11) , 2636-2648
A Second-Generation Route to the Cereblon Fragment of ARV-471, Vepdegestrant
- 9 September 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (9) , 2410-2422
Development of Scalable Synthesis of Chiral Sultam via a Chiral Phosphoric Acid-Promoted tert-Butyl Carbamate Deprotection–Resolution Sequence or Diastereoselective Hydrogenation
- 9 September 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (9) , 2410-2422
Development of Scalable Synthesis of Chiral Sultam via a Chiral Phosphoric Acid-Promoted tert-Butyl Carbamate Deprotection–Resolution Sequence or Diastereoselective Hydrogenation
- 15 May 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (6) , 1554-1559
Cu-Catalyzed Coupling of Aryl Halides Utilizing Ammonia and Hydroxypicolinamide Ligands
- 15 May 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (6) , 1554-1559
Cu-Catalyzed Coupling of Aryl Halides Utilizing Ammonia and Hydroxypicolinamide Ligands
- 8 November 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (12) , 4420-4430
Asymmetric Synthesis of the cis-1,2-Diaryltetralin Vepdegestrant Core via an Enantioselective Intramolecular Corey-Chaykovsky Epoxidation
- 8 November 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (12) , 4420-4430
Asymmetric Synthesis of the cis-1,2-Diaryltetralin Vepdegestrant Core via an Enantioselective Intramolecular Corey-Chaykovsky Epoxidation
- Open Access
- 23 August 2024
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 10 (9) , 1674-1688
C–H Labeling with [18F]Fluoride: An Emerging Methodology in Radiochemistry
Fluorine-18 is the most routinely employed radioisotope for positron emission tomography, a dynamic nuclear imaging modality. The radiolabeling of C-H bonds is an attractive method for installing fluorine-18 into organic molecules since it can preclude the cumbersome prefunctionalization of requisite precursors. Although electrophilic "F+" reagents (e.g., [18F]F2) are effective for C-H radiolabeling, state-of-the-art methodologies predominantly leverage high molar activity nucleophilic [18F]fluoride sources (e.g., [18F]KF) with substantial (pre)clinical advantages. Reflecting this, multiple nucleophilic C-H radiolabeling techniques of high utility have been disclosed over the past decade. However, the adoption of (pre)clinical C-H radiolabeling has been slow, and PET imaging agents are still routinely prepared via methods that, despite a high level of practicality, are limited in scope (e.g., SNAr, SN2 radiofluorinations). By addressing the drawbacks inherent to these strategies, C-H radiofluorination and radiofluoroalkylation carry the potential to complement and supersede state-of-the-art labeling methods, facilitating the expedited production of PET agents used in disease staging and drug development. In this Outlook, we showcase recent C-H labeling developments with fluorine-18 and discuss the merits, potential, and barriers to adoption in (pre)clinical settings. In addition, we highlight trends, challenges, and directions in this emerging field of study.
- 23 August 2024
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 10 (9) , 1674-1688
Open AccessC–H Labeling with [18F]Fluoride: An Emerging Methodology in Radiochemistry
Fluorine-18 is the most routinely employed radioisotope for positron emission tomography, a dynamic nuclear imaging modality. The radiolabeling of C-H bonds is an attractive method for installing fluorine-18 into organic molecules since it can preclude the cumbersome prefunctionalization of requisite precursors. Although electrophilic "F+" reagents (e.g., [18F]F2) are effective for C-H radiolabeling, state-of-the-art methodologies predominantly leverage high molar activity nucleophilic [18F]fluoride sources (e.g., [18F]KF) with substantial (pre)clinical advantages. Reflecting this, multiple nucleophilic C-H radiolabeling techniques of high utility have been disclosed over the past decade. However, the adoption of (pre)clinical C-H radiolabeling has been slow, and PET imaging agents are still routinely prepared via methods that, despite a high level of practicality, are limited in scope (e.g., SNAr, SN2 radiofluorinations). By addressing the drawbacks inherent to these strategies, C-H radiofluorination and radiofluoroalkylation carry the potential to complement and supersede state-of-the-art labeling methods, facilitating the expedited production of PET agents used in disease staging and drug development. In this Outlook, we showcase recent C-H labeling developments with fluorine-18 and discuss the merits, potential, and barriers to adoption in (pre)clinical settings. In addition, we highlight trends, challenges, and directions in this emerging field of study.
- 8 February 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (2) , 373-381
Strategies for the Production of [11C]LY2795050 for Clinical Use
This report describes a comparison of four different routes for the clinical-scale radiosynthesis of the κ-opioid receptor antagonist [11C]LY2795050. Palladium-mediated radiocyanation and radiocarbonylation of an aryl iodide precursor as well as copper-mediated radiocyanation of an aryl iodide and an aryl boronate ester have been investigated. Full automation of all four methods is reported, each of which provides [11C]LY2795050 in sufficient radiochemical yield, molar activity, and radiochemical purity for clinical use. The advantages and disadvantages of each radiosynthesis method are compared and contrasted.
- 8 February 2023
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 27 (2) , 373-381
Strategies for the Production of [11C]LY2795050 for Clinical Use
This report describes a comparison of four different routes for the clinical-scale radiosynthesis of the κ-opioid receptor antagonist [11C]LY2795050. Palladium-mediated radiocyanation and radiocarbonylation of an aryl iodide precursor as well as copper-mediated radiocyanation of an aryl iodide and an aryl boronate ester have been investigated. Full automation of all four methods is reported, each of which provides [11C]LY2795050 in sufficient radiochemical yield, molar activity, and radiochemical purity for clinical use. The advantages and disadvantages of each radiosynthesis method are compared and contrasted.
- 18 April 2022
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 144 (16) , 7422-7429
Copper-Mediated Radiocyanation of Unprotected Amino Acids and Peptides
This report describes a copper-mediated radiocyanation of aryl halides that is applicable to complex molecules. This transformation tolerates an exceptionally wide range of functional groups, including unprotected amino acids. As such, it enables the site-specific introduction of 11C[CN] into peptides at an iodophenylalanine residue. The use of a diamine-ligated copper(I) mediator is crucial for achieving high radiochemical yield under relatively mild conditions, thus limiting racemization and competing side reactions of other amino acid side chains. The reaction has been scaled and automated to deliver radiolabeled peptides, including analogues of adrenocorticotropic hormone 1–27 (ACTH) and nociceptin (NOP). For instance, this Cu-mediated radiocyanation was leveraged to prepare >40 mCi of [11C]cyano-NOP to evaluate biodistribution in a primate using positron emission tomography. This investigation provides preliminary evidence that nociceptin crosses the blood-brain barrier and shows uptake across all brain regions (SUV >1 at 60 min post-injection), consistent with the known distribution of NOP receptors in the rhesus brain.
- 18 April 2022
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 144 (16) , 7422-7429
Copper-Mediated Radiocyanation of Unprotected Amino Acids and Peptides
This report describes a copper-mediated radiocyanation of aryl halides that is applicable to complex molecules. This transformation tolerates an exceptionally wide range of functional groups, including unprotected amino acids. As such, it enables the site-specific introduction of 11C[CN] into peptides at an iodophenylalanine residue. The use of a diamine-ligated copper(I) mediator is crucial for achieving high radiochemical yield under relatively mild conditions, thus limiting racemization and competing side reactions of other amino acid side chains. The reaction has been scaled and automated to deliver radiolabeled peptides, including analogues of adrenocorticotropic hormone 1–27 (ACTH) and nociceptin (NOP). For instance, this Cu-mediated radiocyanation was leveraged to prepare >40 mCi of [11C]cyano-NOP to evaluate biodistribution in a primate using positron emission tomography. This investigation provides preliminary evidence that nociceptin crosses the blood-brain barrier and shows uptake across all brain regions (SUV >1 at 60 min post-injection), consistent with the known distribution of NOP receptors in the rhesus brain.
- 3 September 2021
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 60 (18) , 14349-14356
Accessing Molecular Dimeric Ir Water Oxidation Catalysts from Coordination Precursors
One ongoing challenge in the field of iridium-based water oxidation catalysts is to develop a molecular precatalyst affording well-defined homogeneous active species for catalysis. Our previous work by using organometallic precatalysts Cp*Ir(pyalk)OH and Ir(pyalk)(CO)2 (pyalk = (2-pyridyl)-2-propanolate) suggested a μ-oxo-bridged Ir dimer as the probable resting state, although the structure of the active species remained elusive. During the activation, the ligands Cp* and CO were found to oxidatively degrade into acetic acid or other products, which coordinate to Ir centers and affect the catalytic reaction. Two related dimers bearing two pyalk ligands on each iridium were crystallized for structural analysis. However, preliminary results indicated that these crystallographically characterized dimers are not active catalysts. In this work, we accessed a mixture of dinuclear iridium species from a coordination precursor, Na[Ir(pyalk)Cl4], and assayed their catalytic activity for oxygen evolution by using NaIO4 as the oxidant. This catalyst showed comparable oxygen-evolution activity to the ones previously reported from organometallic precursors without demanding oxidative activation to remove sacrificial ligands. Future research along this direction is expected to provide insights and design principles toward a well-defined active species.
- 3 September 2021
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 60 (18) , 14349-14356
Accessing Molecular Dimeric Ir Water Oxidation Catalysts from Coordination Precursors
One ongoing challenge in the field of iridium-based water oxidation catalysts is to develop a molecular precatalyst affording well-defined homogeneous active species for catalysis. Our previous work by using organometallic precatalysts Cp*Ir(pyalk)OH and Ir(pyalk)(CO)2 (pyalk = (2-pyridyl)-2-propanolate) suggested a μ-oxo-bridged Ir dimer as the probable resting state, although the structure of the active species remained elusive. During the activation, the ligands Cp* and CO were found to oxidatively degrade into acetic acid or other products, which coordinate to Ir centers and affect the catalytic reaction. Two related dimers bearing two pyalk ligands on each iridium were crystallized for structural analysis. However, preliminary results indicated that these crystallographically characterized dimers are not active catalysts. In this work, we accessed a mixture of dinuclear iridium species from a coordination precursor, Na[Ir(pyalk)Cl4], and assayed their catalytic activity for oxygen evolution by using NaIO4 as the oxidant. This catalyst showed comparable oxygen-evolution activity to the ones previously reported from organometallic precursors without demanding oxidative activation to remove sacrificial ligands. Future research along this direction is expected to provide insights and design principles toward a well-defined active species.
- 29 April 2021
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 143 (18) , 6915-6921
Sequential Ir/Cu-Mediated Method for the Meta-Selective C–H Radiofluorination of (Hetero)Arenes
This article describes a sequential Ir/Cu-mediated process for the meta-selective C–H radiofluorination of (hetero)arene substrates. In the first step, Ir-catalyzed C(sp2)–H borylation affords (hetero)aryl pinacolboronate (BPin) esters. The intermediate organoboronates are then directly subjected to copper-mediated radiofluorination with [18F]tetrabutylammonium fluoride to afford fluorine-18 labeled (hetero)arenes in high radiochemical yield and radiochemical purity. This entire process is performed on a benchtop without Schlenk or glovebox techniques and circumvents the need to isolate (hetero)aryl boronate esters. The reaction was automated on a TracerLab FXFN module with 1,3-dimethoxybenzene and a meta-tyrosine derivative. The products, [18F]1-fluoro-3,5-dimethoxybenzene and an 18F-labeled meta-tyrosine derivative, were obtained in 37 ± 5% isolated radiochemical yield and >99% radiochemical purity and 25% isolated radiochemical yield and 99% radiochemical purity, and 0.52 Ci/μmol (19.24 GBq/μmol) molar activity (Am), respectively.
- 29 April 2021
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 143 (18) , 6915-6921
Sequential Ir/Cu-Mediated Method for the Meta-Selective C–H Radiofluorination of (Hetero)Arenes
This article describes a sequential Ir/Cu-mediated process for the meta-selective C–H radiofluorination of (hetero)arene substrates. In the first step, Ir-catalyzed C(sp2)–H borylation affords (hetero)aryl pinacolboronate (BPin) esters. The intermediate organoboronates are then directly subjected to copper-mediated radiofluorination with [18F]tetrabutylammonium fluoride to afford fluorine-18 labeled (hetero)arenes in high radiochemical yield and radiochemical purity. This entire process is performed on a benchtop without Schlenk or glovebox techniques and circumvents the need to isolate (hetero)aryl boronate esters. The reaction was automated on a TracerLab FXFN module with 1,3-dimethoxybenzene and a meta-tyrosine derivative. The products, [18F]1-fluoro-3,5-dimethoxybenzene and an 18F-labeled meta-tyrosine derivative, were obtained in 37 ± 5% isolated radiochemical yield and >99% radiochemical purity and 25% isolated radiochemical yield and 99% radiochemical purity, and 0.52 Ci/μmol (19.24 GBq/μmol) molar activity (Am), respectively.
- 10 April 2020
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 142 (16) , 7362-7367
NHC-Copper Mediated Ligand-Directed Radiofluorination of Aryl Halides
[18F]-labeled aryl fluorides are widely used as radiotracers for positron emission tomography (PET) imaging. Aryl halides (ArX) are particularly attractive pre-cursors to these radiotracers, as they are readily available, inexpensive, and stable. However, to date, the direct preparation of [18F]-aryl fluorides from aryl halides remains limited to SNAr reactions between highly activated ArX substrates and K18F. This report describes an aryl halide radiofluorination reaction in which the C(sp2)–18F bond is formed via a copper-mediated pathway. Copper N-heterocyclic carbene complexes serve as mediators for this transformation, using aryl halide substrates with directing groups at the ortho position. This reaction is applied to the radiofluorination of electronically diverse aryl halide derivatives, including the bioactive molecules vismodegib and PH-089.
- 10 April 2020
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 142 (16) , 7362-7367
NHC-Copper Mediated Ligand-Directed Radiofluorination of Aryl Halides
[18F]-labeled aryl fluorides are widely used as radiotracers for positron emission tomography (PET) imaging. Aryl halides (ArX) are particularly attractive pre-cursors to these radiotracers, as they are readily available, inexpensive, and stable. However, to date, the direct preparation of [18F]-aryl fluorides from aryl halides remains limited to SNAr reactions between highly activated ArX substrates and K18F. This report describes an aryl halide radiofluorination reaction in which the C(sp2)–18F bond is formed via a copper-mediated pathway. Copper N-heterocyclic carbene complexes serve as mediators for this transformation, using aryl halide substrates with directing groups at the ortho position. This reaction is applied to the radiofluorination of electronically diverse aryl halide derivatives, including the bioactive molecules vismodegib and PH-089.